The Company’s near-term plans are to submit market applications in multiple countries for Compass's anti-viral drugs and to complete Phase I safety, immunology & efficacy studies of the HCV vaccine in humans. The two Companies together will create value by achieving major developmental milestones, by generating revenue from the sales of anti-viral drugs and obtaining proof in humans that VLP vaccine immunization leads to development of neutralizing antibodies that attack the HCV virus and prevent infection.

The Company will continue to advance the development of other anti-viral pipeline products and we plan to begin Phase II efficacy studies of the VLP vaccine as a potential anti-viral immunotherapy for treating chronic HCV infection. An antibody product derived from healthy volunteers administered VLP vaccine inoculations will be evaluated as a passive immunotherapy product in patients undergoing liver transplantation to prevent or significantly delay the liver graft re-infection by the hepatitis C virus.